BOM:524396'
s Current Ratio Range Over the Past 10 Years
Min: 1.17 Med: 1.38 Max: 6.23
Current: 1.73
During the past 13 years, Biofil Chemicals & Pharmaceuticals's highest Current Ratio was 6.23. The lowest was 1.17. And the median was 1.38.
BOM:524396's Current Ratio is ranked worse than 58.6% of 1000
companies
in the Drug Manufacturers industry
Industry Median: 2
vs BOM:524396: 1.73
Biofil Chemicals & Pharmaceuticals (BOM:524396) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Biofil Chemicals & Pharmaceuticals Current Ratio Related Terms
Biofil Chemicals & Pharmaceuticals Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biofil Chemicals & Pharmaceuticals Current Ratio Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Biofil Chemicals & Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biofil Chemicals & Pharmaceuticals Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biofil Chemicals & Pharmaceuticals's Current Ratio distribution charts can be found below:
* The bar in red indicates where Biofil Chemicals & Pharmaceuticals's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biofil Chemicals & Pharmaceuticals (BOM:524396) has a Current Ratio of 1.73 as of Mar. 2026. This is 25% above median its historical median of 1.38. Over the past decade, Biofil Chemicals & Pharmaceuticals' Current Ratio has ranged from 1.17 to 6.23. According to the industry distribution chart, Biofil Chemicals & Pharmaceuticals ranks #586 out of 1000 companies in the Drug Manufacturers industry, placing it in the top 58.6%.
Is Biofil Chemicals & Pharmaceuticals' Current Ratio too high?
Biofil Chemicals & Pharmaceuticals' current Current Ratio of 1.73 is 25% above median its 10-year median of 1.38. Over the past 10 years, this metric has ranged from a low of 1.17 to a high of 6.23. The Drug Manufacturers industry median Current Ratio is 2.00. Biofil Chemicals & Pharmaceuticals' value of 1.73 is 13.5% below this industry median. Based on the distribution chart, Biofil Chemicals & Pharmaceuticals ranks #586 out of 1000 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Biofil Chemicals & Pharmaceuticals has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biofil Chemicals & Pharmaceuticals' Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Biofil Chemicals & Pharmaceuticals ranks #586 out of 1000 companies for Current Ratio. This places Biofil Chemicals & Pharmaceuticals in the lower half of its industry. The industry median Current Ratio is 2.00. Biofil Chemicals & Pharmaceuticals' value of 1.73 is 13.5% below this benchmark. Historically, Biofil Chemicals & Pharmaceuticals' own Current Ratio has ranged from 1.17 to 6.23 over the past decade. While the company's 10-year median is 1.38 vs. the industry median of 2.00, Biofil Chemicals & Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 1,000 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biofil Chemicals & Pharmaceuticals's current Current Ratio of 1.73 is 13.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biofil Chemicals & Pharmaceuticals's current Current Ratio is 1.73, which is 25% above median its own 10-year median of 1.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofil Chemicals & Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Biofil Chemicals & Pharmaceuticals (BOM:524396) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹41.80, compared to a current price of ₹34.07 — trading 18.5% below its estimated fair value. The current Current Ratio is 1.73, which is 25% above median its 10-year median of 1.38 and 13.5% below the Drug Manufacturers industry median of 2.00. Biofil Chemicals & Pharmaceuticals' overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Biofil Chemicals & Pharmaceuticals (BOM:524396), the current Current Ratio is 1.73 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biofil Chemicals & Pharmaceuticals (BOM:524396) Overvalued in 2026?
Based on GuruFocus' analysis, Biofil Chemicals & Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹34.07 is trading 18.5% below its estimated GF Value™ of ₹41.80.
GuruFocus considers Biofil Chemicals & Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for BOM:524396:
Current Ratio: 1.73 (25% above median its 10-year median of 1.38)
GF Value™: ₹41.80 vs. price of ₹34.07 (18.5% below fair value)
Industry Position: 13.5% below the Drug Manufacturers median (#586 of 1000)
No single metric tells the full story. See the BOM:524396 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biofil Chemicals & Pharmaceuticals Business Description
Biofil Chemicals & Pharmaceuticals Ltd is an Indian pharmaceutical company. It deals in the manufacturing and trading of pharmaceuticals. Further, the company also deals in providing job work facilities with respect to the manufacturing of pharmaceutical drugs. Its product portfolio comprises basic drugs and pharmaceuticals such as sodium citrate, sodium chloride, ferrous sulphate, micro crystalline cellulose, dicyclomine hydrochloride, and others. The company's operating segments are: Pharma, which derives maximum revenue, and Chemicals. Geographically, it caters to both domestic and international markets.
74GF Score
Get the complete analysis for BOM:524396
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524396 has been successfully added to your 
